A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (LANTIMA)
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
Sponsor: Ipsen
This PHASE1/PHASE2 trial investigates Spasticity and is currently actively recruiting participants. Ipsen leads this study, which shows 39 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
39 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Active Not Recruiting → Recruiting
▶ Show 34 earlier versions
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Barcelona, Spain , Bastia, France , Bonn, Germany , Bordeaux, France , Brescia, Italy , Brest, France , Budapest, Hungary , Dallas, United States , Debrecen, Hungary and 58 more locations